n-Lorem's personalized SCN2A ASO tied to seizure drop in one child
A single-patient trial of a custom antisense drug for a sodium-channel epilepsy mutation reported symptom improvement and no drug-related adverse events, a case report rather than a controlled result.
Executive Summary
- A first-in-human, single-patient study of a custom antisense drug for a rare sodium-channel epilepsy mutation reported seizure reduction and developmental gains in the treated child, with no drug-related safety findings over extended follow-up.
- The trial is an early-phase, open-label, single-patient study built around one child's specific genetic mutation, a model designed for diseases too rare to run a conventional controlled trial.
- The result supports the feasibility and safety of allele-selective antisense therapy tailored to an individual mutation, a model that could extend to other patients with similarly rare sodium-channel variants, but it does not establish efficacy in a way that generalizes beyond the single case.
- The findings arrive through the sponsor's own announcement in language flagged as promotional, underscoring that a one-patient, uncontrolled case cannot be read as a validated treatment effect.
The publication
n-Lorem Foundation, a nonprofit that designs individualized ASO drugs for patients with mutations found in fewer than 30 people worldwide, said Nature Medicine published treatment results from two single-patient trials of allele-selective ASOs, each built around one child's SCN2A mutation. One of the two trials is registered as NCT06314490, a Phase 1/2 study titled "Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A," sponsored through the University of California, San Diego and enrolling a single patient. SCN2A mutations disrupt an essential sodium channel and are a recognized cause of severe early-life epilepsy with profound developmental impairment. Impressive+1Impressive Benefits and an Excellent Safety and Tolerability Profiles in Two Severely Affected Patients With Mutations in a Vital Sodium Channel (SCN2A) Treated With Bespoke ASOs Reported in Nature MedicineJul 21, 2026Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2ANCT06314490
The result
The disclosed result describes reductions in seizures, motor and developmental improvement including a new milestone of independent walking, and improved gastrointestinal and autonomic function in one patient, sustained over more than two years without an ASO-related adverse event or serious adverse event. n-Lorem's registered primary outcome measure for NCT06314490 is a gastrointestinal assessment using the Bristol Stool Chart, a narrower, prespecified metric than the seizure and developmental gains emphasized in the publication and the company's release. Impressive+1Impressive Benefits and an Excellent Safety and Tolerability Profiles in Two Severely Affected Patients With Mutations in a Vital Sodium Channel (SCN2A) Treated With Bespoke ASOs Reported in Nature MedicineJul 21, 2026Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2ANCT06314490
How it was done
The design is a first-in-human, single-patient, open-label study using a modified cross-over structure, with one allele-selective ASO manufactured specifically to silence the mutant SCN2A allele while sparing the normal one. The trial enrolled its single target patient, reached its primary completion date on February 16, 2026, and is now listed as active, not recruiting. With one patient and no control arm, the study is built to test feasibility and safety of a bespoke molecule, not to establish a generalizable efficacy estimate. Impressive+1Impressive Benefits and an Excellent Safety and Tolerability Profiles in Two Severely Affected Patients With Mutations in a Vital Sodium Channel (SCN2A) Treated With Bespoke ASOs Reported in Nature MedicineJul 21, 2026Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2ANCT06314490
Sponsor framing
Stanley Crooke, n-Lorem's CEO, said the foundation is "thrilled with the benefits we are observing in ASO-treated patients" and pointed to a favorable safety record across more than 50 patients treated under its program. Elizabeth Berry-Kravis, an investigator at Rush University Medical Center involved in a related SCN2A case, said the findings suggest "developmental trajectories may be more dynamic than we have traditionally believed". Both are enthusiastic characterizations of a single treated child's trajectory, and the underlying data carry the flags common to any n-of-1 report: no comparator, immature follow-up relative to the child's lifespan, and a sponsor with a direct interest in the platform's success. ImpressiveImpressive Benefits and an Excellent Safety and Tolerability Profiles in Two Severely Affected Patients With Mutations in a Vital Sodium Channel (SCN2A) Treated With Bespoke ASOs Reported in Nature MedicineJul 21, 2026
The broader program
n-Lorem operates as a single-sponsor program built entirely around this personalized-ASO model, with its one tracked SCN2A trial currently active, not recruiting. The foundation's model, custom ASOs manufactured and delivered for free to patients with mutations too rare for a commercial drug program, has no direct comparator disclosed in the competitive trial data reviewed for this case, leaving the SCN2A result to stand on its own as a demonstration of feasibility for allele-selective, mutation-specific dosing rather than as a benchmarked efficacy result. NCT06314490Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2ANCT06314490
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.